Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Roche Holding AG’s shares just posted their best month since 1997, lifted by optimism over an experimental breast cancer pill and encouraging trial results. Analysts see further gains ahead.

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...

More than nine in 10 patients treated with Roche’s next-generation Alzheimer’s disease antibody trontinemab tested negative for amyloid plaques in a mid-stage study, marking a return to the ...

Designed for use in doctor’s offices, clinics and emergency rooms, the PCR diagnostic aims to deliver results in fewer than ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

Roche has secured CE Mark approval for its cobas BV/CV assay to support the diagnosis of infectious causes of vaginitis.

Roche's giredestrant cut recurrence risk by 30% in the phase 3 lidERA study, showing strong benefits in early ER-positive ...

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive investment.

The stock gained 19% last month after Roche said its giredestrant medicine helped women with a form of early breast cancer. Additionally, news of two late-stage trials showed that a multiple sclerosis ...